This meeting is sponsored by:
PROGRAMME - all times are UK time (GMT)
| 09.00 - 10.00 | Arrival, registration and coffee |
| 10.00 - 10.30 | Welcome and introduction - Mike Hann, GSK, UK Targeted covalent inhibitors and molecular superglues Lyn Jones, Dana-Farber Cancer Institute, Boston, USA |
| Session 1 - Part 1: Sources of target hypotheses for drug discovery | |
| 10.30 - 11.00 | The utility of human genetics, clinical samples and collaboration in drug discovery for IPF Jessica Eley, GSK, Stevenage, UK |
| 11.00 - 11.30 | Using Systems Biology to Discover Novel Targets for Neurological Diseases Victor Neduva, MSD, London, UK |
| 11.30 - 12.00 | Coffee break |
| Session 1 - Part 2: Sources of target hypotheses for drug discovery | |
| 12.00 - 12.30 | Chemogenomic screening to identify novel mechanisms which selectively kill HIV infected cells Deb Rothman, Merck, USA |
| 12.30 - 13.00 | Single cell atlases of the gut to discover and prioritise druggable targets Rasa Elmentaite, Teichmann Group, University of Cambridge, UK |
| 13.00 - 14.00 | Lunch break |
| Session 2: Practicalities of assessing target intervention opportunities | |
| 14.00 - 14.30 | In silico target identification and prioritisation in the era of new drug modalities Andrew Leach, EBI, Cambridge, UK |
| 14.30 - 15.00 | Adapting to a changing portfolio landscape: an industry perspective of experimental approaches to assess target tractability and hit finding Ian Storer, AZ, Cambridge, UK |
| 15.00 - 15.30 | Affinity Selection Mass Spectrometry for Experimental Tractability Assessment
Joe Kozole, GSK, Philadelphia, USA |
| 15.30 - 16.00 | Novel Therapeutic Targets for Treatment of Neurodegeneration
Paul Brennan, University of Oxford, UK |
| 16.00 | Closing comments and meeting close |